深度聚焦！光伏板块强势反弹，德业股份领衔涨停潮

光伏板块强势反弹，德业股份领衔涨停潮

上海 - 6月13日，A股市场光伏板块震荡反弹，德业股份(605117)涨停，成为板块最大亮点。泉为科技(002872)涨超10%，鹿山新材(002732)、金刚光伏(300815)、东方日升(300282)等跟涨。

**消息面上，**彭博新能源财经和伍德麦肯兹发布的研究报告显示，预计到2025年，全球累计户用光伏装机将达535GW，家庭储能容量达58.26GWh，户用光储市场正迎来繁荣发展期。

德业股份是国内领先的光伏组件制造商，公司主营业务包括光伏组件的研发、生产和销售。公司拥有完整的产业链布局，具备较强的综合竞争力。

**光伏板块近期表现低迷，**主要受硅料价格高企、组件价格下跌等因素影响。但随着国内外光伏需求持续增长，光伏板块长期向好趋势依然不变。

**业内人士表示，**随着硅料价格逐渐企稳回落，以及光伏电站招标规模的扩大，光伏板块有望迎来反弹行情。德业股份作为光伏行业的龙头企业，有望充分受益于行业发展红利。

以下是德业股份近期的主要表现：

• 2024年第一季度，公司实现营业收入21.5亿元，同比增长52.36%；实现净利润2.3亿元，同比增长61.22%。
• 公司预计2024年全年实现营业收入80亿元至90亿元，同比增长40%至50%；实现净利润7.5亿元至8.5亿元，同比增长50%至60%。

**德业股份此次涨停，**反映了市场对公司未来发展前景的看好。随着公司产能的不断释放，以及光伏行业景气度的持续提升，德业股份有望实现业绩的进一步增长。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.